Twitter

About adaptsmart-admin

This author has not yet filled in any details.
So far adaptsmart-admin has created 28 blog entries.

“MAPPs can be a promising way of working”: Podcast with HTA’s and Payers From DIA Hamburg 2016

On 7 April, key participants associated with the IMI ADAPT SMART project met to discuss the consortia's progress in finding ways to implement MAPPs in Europe. Participants included: Hans-Georg Eichler, Senior Medical Officer at the European Medicines Agency (EMA); Luk Maes, Executive Director, Regulatory Scientific Policies – Europe, for Bristol-Myers Squibb; Ad Schuurman, Head of the Business Contact Centre & International Affairs National Health Care Institute of the Netherlands (ZIN); and Sarah Garner Associate Science Policy and Research, National Institute of Health and Care Excellence (NICE).

MAPPs Q&A

This Q&A aims to address some frequently addressed queries around MAPPs. MAPPs, broadly, are a multi-stakeholder approach to developing an "RCT-plus" to evaluating new medicines. In order for outcomes-based healthcare to succeed, we need to know the performance of a treatment, both at a population level and an individual level. We need to expand [...]

ADAPT SMART – Public survey on EMA pilot on adaptive pathways

One of the workstream has been tasked to review lessons of EMA pilot on Adaptive Pathways. A survey has been developed to capture the experience of the industry and other organisations with the EMA pilot on Adaptive Pathways. The survey consists of two parts: - One EMA questionnaire for those companies which actually submitted an [...]

Podcast on Managed Entry: Claudine Sapede-Kniffel of F. Hoffmann-La Roche and Jacoline Bouvy of NICE

On 17th February, Jacoline Bouvy of NICE and Claudine Sapede of F. Hoffmann-La Roche met in London to discuss managed entry in the context of the ADAPT SMART initiative.

ADAPT SMART Workshop: Selection Criteria for MAPPs – Exploring and aligning stakeholder needs

29th February 2016

Amsterdam, The Netherlands

On the 29th of February, ADAPT SMART will be hosting an invitation-only multi-stakeholder workshop around selection criteria for MAPPs in Amsterdam, The Netherlands. MAPPs seek to foster access to beneficial treatments for the right patient groups at the earliest appropriate time in the product life span in a sustainable and affordable fashion.

Webinar Report: Status Updates from ADAPT SMART Work Package Leads 

On 8th January 2016, the ADAPT SMART work package leads participated in a webinar to share status updates, and compare notes on progress made and hurdles to overcome. ADAPT SMART Consortia members were invited to participate in the webinar, and were invited to ask questions via live chat after the work package leads finished their [...]

Podcast: Views from André Broekmans and Luk Maes, Work Package 2 Leads

In December 2015, ADAPT SMART work package leads André Broekmans and Luk Maes met to discuss the ambitious objectives of ADAPT SMART, the impact of the diverse participants involved in the project, and what sets this initiative apart from other programmes focussed on MAPPs.

Editorial Contribution: André Broekmans, Coordinator ADAPT SMART, Looks Ahead

With the first few months of the ADAPT SMART project underway, coordinator André Broekmans (Escher Platform, TI Pharma) shares his views on what is needed to continue to drive the project forward.

ADAPT SMART Round Table – Thought leaders discuss objectives and approaches for success

On 27th October, thought leaders in the field of adaptive pathways met in Washington D.C. to discuss the global objectives of IMI ADAPT SMART and what the landmark project hopes to achieve.

ADAPT SMART Kick-off Meeting – The Innovative Medicines Initiative’s ADAPT SMART: Laying the Foundations and Building Consensus to Make MAPPs Work for All

On Friday September 4th, 2015, a coalition of 90 European healthcare stakeholders from 32 organisations including patients, payers, regulators, HTAs, academic institutions, and industry took their first steps towards investigating MAPPs tools and methodologies, and engaging in a dialogue with all relevant stakeholders to prove and develop workable MAPPs concepts.

 

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115890. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.